Racura Oncology Cleared to Escalate RC220 to 100 mg/m2 in Phase 1 HARNESS-1 Trial in EGFR-Mutant Non-Small Cell Lung Cancer

Phase 1positiveRC220osimertinibPositive

AI Analysis

Summary

Racura Oncology's RC220 in combination with osimertinib has been cleared to escalate to 100 mg/m2 in the Phase 1 HARNESS-1 trial after demonstrating no dose-limiting toxicities in initial cohort of EGFR-mutant non-small cell lung cancer patients.

Clinical Trial Data

Phase

Patients

Outcome Details

Safety Review Committee identified no dose-limiting toxicities or treatment-related safety concerns in Cohort 1 and recommended escalation to 100 mg/m2 dose level

Importance:5/10

Sentiment:

0.70

Phase 1oncologylung cancerdose escalationsafety

Related Companies

$DFPH

Read the original article

Published by PR Newswire Biotech on October 12, 2026 11:00 AM

Read Original